23andMe founder Anne Wojcicki is set to regain control of the DNA company's assets after TTAM Research Institute outbid Regeneron with a $305 million offer, following a bankruptcy auction.
A bankruptcy judge has approved the reopening of bidding, with Regeneron declining to top Wojcicki's offer, leaving 23andMe in TTAM's control pending court approval on June 17, 2025.
Regeneron had previously planned to retain all employees and continue offering DNA testing kits, utilizing 23andMe's genetic data for health risk identification and drug target research.
TTAM Research Institute, led by Wojcicki, has committed to various data and privacy protections for 23andMe customers, such as data deletion options, research opt-outs, and consumer privacy safeguards.
Wojcicki's goal to maintain control of the company has been evident since she resigned as CEO to bid on 23andMe upon its bankruptcy declaration in March 2025.
She emphasizes the mission of 23andMe to empower individuals with genetic data transparency and choice, ensuring customers can learn about their ancestry and health risks at their discretion.
23andMe faced challenges before bankruptcy, including a 2023 data breach affecting millions and mass layoffs in 2024 affecting 40% of the workforce.